CDKN1B and cancer: We showed that PAK1 inhibition reduced tumor cell migration in multiple types of cancer cells harboring p27 mislocalization, including fibrosarcoma, breast cancer, and renal carcinoma, suggesting that the cytoplasmic p27‐mediated PAK1 activation may be extended to other types of cancer.